NCT07147127Not yet recruiting
Anti-citrullinated SR-A Peptide (Anti-csp) Antibody as a Biomarker in Rheumatoid Arthritis (RA).
Anti-Citrullinated SR-A Peptide (Anti-csp)Antibody as a Biomarker for Rheumatoid Arthritis.
Source: ClinicalTrials.gov · Last updated 28 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
1. To measure serum level of anticitrullinated SR-A peptide antibody (anti-CSP) in RA patients compared to healthy controls . 2. To assess the diagnostic performance of anti-CSP for RA specifically seronegative RA patients. 3. To evaluate correlation of serum anti-CSP level with disease activity and functional disability scores in RA patients.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 81 (estimated)
- First submitted
- 9 Aug 2025
- Start date
- 1 Jan 2026
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Walaa sharif Eid Ahmed
- Diseases
- Rheumatoid arthritis
- NCT number
- NCT07147127
What you commit to
- Study type: Observational
- Planned participants: 81
- From 1 Jan 2026 to the primary completion date, 31 Dec 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with other autoimmune or connective tissue diseases (e.g., SLE, SS) .
- Patients with chronic infections or malignancies .
Age
- Patients less than18 years old .
Who the study is looking for
- Adults (≥18 years old)
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.